Overview
Equillium is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics targeting immuno-inflammatory pathways for severe autoimmune and inflammatory disorders. Key pipeline assets include itolizumab, licensed from Biocon for acute graft-versus-host disease and ulcerative colitis, and EQ504, a potent aryl hydrocarbon receptor modulator for skin, gastrointestinal, and lung diseases. The company focuses on non-immunosuppressive mechanisms to restore immune balance with high unmet medical need.
Frequently asked questions
- What are Equillium's main therapeutic areas and pipeline assets?
- Equillium develops therapeutics for severe autoimmune and inflammatory disorders, including itolizumab for acute graft-versus-host disease (aGVHD) and ulcerative colitis (UC), and EQ504, an aryl hydrocarbon receptor (AhR) modulator for skin, gastrointestinal, and inflammatory lung diseases.
- What is the regulatory status of Equillium's lead candidates?
- Itolizumab has received FDA feedback on Accelerated Approval pathway for first-line aGVHD treatment and showed positive Phase 2 data in UC with 23.3% clinical remission. EQ504 is advancing into clinic with up to $50M financing.
- What are Equillium's geographic rights and partnerships?
- Equillium holds exclusive rights to develop and commercialize itolizumab in the U.S., Canada, Australia, and New Zealand through a license agreement with Biocon.